Tumor Lysis Syndrome: Implications for Oncology Nursing Practice

被引:5
作者
Webster, Jennifer S. [1 ]
Kaplow, Roberta [2 ]
机构
[1] Georgia Canc Specialists, Atlanta, GA 30308 USA
[2] Emory Univ Hosp, Brookhaven, GA USA
关键词
Oncologic emergencies; Tumor lysis syndrome; Cancer; RASBURICASE; RISK;
D O I
10.1016/j.soncn.2021.151136
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: To provide an overview of tumor lysis syndrome, which is one of the metabolic oncologic emergencies. Data Sources: A review and synthesis of empirical articles. Conclusion: One of the metabolic oncologic emergencies identified by the Oncology Nursing Society is tumor lysis syndrome. This condition is life-threatening and is characterized by metabolic derangements that can lead to acute kidney injury and multiple organ dysfunction. Normal intracellular components (potassium, phosphorus, and nucleic acids) spill into the bloodstream when cancer cells die. If the tumor is large and highly responsive to chemotherapy, the resulting cascade of dead tumor cells may overwhelm normal homeostatic mechanisms. The cells enter the bloodstream faster than they can be cleared by the kidneys. This results in hyperkalemia and hyperphosphatemia. Nucleic acids convert to uric acid in the liver with a resultant hyperuricemia. Excess uric acid in the kidneys can lead to uric acid nephropathy and renal insufficiency. Phosphorus binds with calcium, leading to hypocalcemia from the formation of calcium phosphate precipitate or crystals. These crystals can also lead to renal insufficiency or acute kidney injury, which can lead to a metabolic acidosis and exacerbation of the hyperkalemic state. These metabolic derangements define presence of tumor lysis syndrome. Implications for Nursing Practice: Multidisciplinary collaboration and communication is essential to identifying patients at risk prior to treatment. Meticulous nursing care in terms of prevention and treatment is critical to patient survival. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页数:6
相关论文
共 31 条
  • [1] Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project
    Allen, Katherine C.
    Champlain, Amanda H.
    Cotliar, Jonathan A.
    Belknap, Steven M.
    West, Dennis P.
    Mehta, Jayesh
    Trifilio, Steven M.
    [J]. DRUG SAFETY, 2015, 38 (02) : 183 - 187
  • [2] Tumor Lysis Syndrome in Patients with Hematological Malignancies
    Belay, Yohannes
    Yirdaw, Ketsela
    Enawgaw, Bamlaku
    [J]. JOURNAL OF ONCOLOGY, 2017, 2017
  • [3] Update on Importance of Diet in Gout
    Beyl, Randall N., Jr.
    Hughes, Laura
    Morgan, Sarah
    [J]. AMERICAN JOURNAL OF MEDICINE, 2016, 129 (11) : 1153 - 1158
  • [4] A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome
    Cairo, Mitchell S.
    Thompson, Stephen
    Tangirala, Krishna
    Eaddy, Michael T.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (03) : 173 - 178
  • [5] Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
    Cairo, Mitchell S.
    Coiffier, Bertrand
    Reiter, Alfred
    Younes, Anas
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (04) : 578 - 586
  • [6] Tumour lysis syndrome: new therapeutic strategies and classification
    Cairo, MS
    Bishop, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (01) : 3 - 11
  • [7] Farkas J., 2020, TUMOR LYSIS SYNDROME
  • [8] Goyal R, 2021, HYPERPHOSPHATEMIA
  • [9] Tumor Lysis Syndrome
    Gupta, Arjun
    Moore, Joseph A.
    [J]. JAMA ONCOLOGY, 2018, 4 (06) : 895 - 895
  • [10] Allopurinol-Induced Stevens-Johnson Syndrome
    Gupta, Sushilkumar Satish
    Sabharwal, Nitin
    Patti, Ravikaran
    Kupfer, Yizhak
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2019, 357 (04) : 348 - 351